Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $155.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 5.70% from the stock’s previous close.
A number of other equities research analysts have also commented on GILD. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday. Royal Bank Of Canada raised their price objective on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Truist Financial raised their price objective on Gilead Sciences from $150.00 to $158.00 and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley decreased their price objective on Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, HSBC raised their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $159.26.
View Our Latest Report on Gilead Sciences
Gilead Sciences Price Performance
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $2.01 EPS. Research analysts expect that Gilead Sciences will post -0.48 earnings per share for the current fiscal year.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the transaction, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. The trade was a 33.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the transaction, the chief financial officer directly owned 164,096 shares in the company, valued at approximately $23,841,507.84. This represents a 1.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 105,000 shares of company stock worth $14,940,540. 0.30% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $15,393,785,000. State Street Corp increased its position in shares of Gilead Sciences by 2.3% during the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Invesco Ltd. increased its position in shares of Gilead Sciences by 2.9% during the fourth quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock valued at $1,912,822,000 after purchasing an additional 444,660 shares during the period. Amundi increased its position in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Finally, Legal & General Group Plc bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $1,316,606,000. 83.67% of the stock is owned by institutional investors.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: JPMorgan raised its price target from $160 to $170 and reaffirmed an “overweight” rating, implying meaningful upside and reflecting confidence in Gilead’s earnings and growth outlook.
- Positive Sentiment: Truist increased its target from $150 to $158 and maintained a “buy” rating, while Cantor Fitzgerald reaffirmed “overweight” with a $155 target. Together, these calls support investor confidence in the stock’s potential.
- Positive Sentiment: Gilead signed a five-year DevOps agreement with Cognizant. The partnership is intended to improve technology infrastructure and business processes by combining Cognizant’s technical capabilities with life-sciences expertise, potentially supporting operational efficiency. Gilead Sciences signs five-year DevOps agreement with Cognizant
- Positive Sentiment: Nurix Therapeutics extended the research term of its Gilead collaboration by two years for an oncology program. The extension indicates continued progress in Gilead’s protein-degradation research pipeline and preserves potential future development opportunities.
- Neutral Sentiment: Morgan Stanley lowered its target modestly from $165 to $163 but retained an “overweight” rating, signaling continued confidence despite slightly reduced expectations.
- Neutral Sentiment: Gilead shares were reported higher in after-hours European trading, but the move does not identify a specific fundamental catalyst and may have limited relevance for U.S. investors.
- Negative Sentiment: Royal Bank of Canada raised its target from $123 to $126 but kept a “sector perform” rating. The new target remains below Gilead’s recent trading level, highlighting valuation concerns and potential downside. Gilead Sciences analyst coverage from Royal Bank of Canada
- Negative Sentiment: A recent analysis argued that Gilead’s growth comes at a high price, with discounted-cash-flow assumptions pointing to valuation risk. This could weigh on sentiment despite the more optimistic analyst targets. Gilead: Buying Growth Isn’t Free, And The Discounted Cash Flow Model Knows It
Gilead Sciences Company Profile
Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.
Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
